This article is more than 5 years old. Information may no longer be current.

CASES-PMS: With formalized training, physicians with varied experience achieved similar results to those highly experienced in carotid stenting

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The varied experience level of physicians in the CASES-PMS trial did not prevent them from attaining similar stenting results as the highly experienced physicians from the SAPPHIRE trial, new study data suggested.

Carotid Artery Stenting With Emboli Protection Surveillance – Post-Marketing Study (CASES-PMS) researchers included patients in their study who were older than 18 years and had de novo atherosclerotic or post-endarterectomy restenotic obstructive lesions in native carotid arteries with either ≥50% carotid stenosis if symptomatic or≥80% carotid stenosis if asymptomatic; and patients with at least one anatomic or physiologic risk factor placing them at high risk for surgery. The primary endpoint was a composite of 30-day major adverse events, which included death, any stroke or MI. The patients (n=1,492) were enrolled at 73 sites from August 2003 to October 2005.

The rate of the primary endpoint was 5%, which met criteria for noninferiority to the prespecified objective performance criteria set by the Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) trial. The 1-year cumulative percentage of major adverse events was 12.5%, and all strokes to 30 days plus ipsilateral stroke between 31 and 360 days were similar in the CASES-PMS trial (5.4%) vs. the SAPPHIRE cohort (4.9%).

“With the formalized training program utilized in this study, physicians with varied experience in carotid stenting can achieve short- and longer-term results similar to the highly experienced SAPPHIRE investigators,” the researchers concluded. “One-year outcomes with CASES-PMS showed little additional neurological morbidity and mortality beyond an acceptable 30-day outcome previously reported, and largely reflects the natural history of a large cohort of patients with a high prevalence of advanced cardiovascular disease at baseline.”

Schreiber TL. J Am Coll Cardiol. 2010;56:49-57.

Follow CardiologyToday.com on Twitter.